The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The firm, which is in the process of being acquired by Danaher, reported strong revenue growth for both its consumables and systems.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.